VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland.
Gibson
Angelia D
AD
D'Orazio
Amy
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide; D018572:Disease-Free Survival; D004317:Doxorubicin; D005047:Etoposide; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology*; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000235:genetics*; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D011241:Prednisone; D000069283:Rituximab; D013997:Time Factors; D019772:Topotecan / Q000008:administration & dosage*; D016896:Treatment Outcome; D014750:Vincristine
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D019772:Topotecan; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D011241:Prednisone